ACCD vs TDOC: Accolade vs Teladoc Stock Comparison: AI Score, Valuation, Performance and Upside
Accolade is a personalized health navigation company focused on guiding employer members through healthcare decisions using human advocates plus technology, while Teladoc is the world's largest telehealth platform covering virtual primary care, mental health via BetterHelp, and chronic disease management. Accolade emphasizes high-touch personalization; Teladoc emphasizes scale and virtual care breadth.
ACCD vs TDOC is personalized health navigation versus scale telehealth — Accolade wins if high-touch human advocacy drives superior employer outcomes and justifies premium PEPM pricing; Teladoc wins if BetterHelp stabilizes, integrated care gains traction, and telehealth becomes the default primary care channel.
ACCD and TDOC are closely matched — they split the tracked metrics evenly.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want small-cap digital health exposure with a differentiated human-plus-technology health navigation model
- believe personalized health advocacy drives better employer ROI than volume-based telehealth
- are comfortable with unprofitability and longer employer client sales cycles
- want exposure to mental health and complex care navigation as a growing employer benefits category
- want the largest telehealth platform with the broadest virtual care product breadth
- believe BetterHelp's consumer mental health platform can stabilize and return to growth
- value Teladoc's global health system partnerships and enterprise employer relationships
- prefer a larger, more liquid digital health company vs a small-cap navigation play
| Metric | ACCD | TDOC |
|---|---|---|
| AI scorei | N/A | 24.6 |
| AI ranki | N/A | #2989 |
| Latest closei | N/A | $5.97 |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ACCD | TDOC |
|---|---|---|
| 1Y ago | N/A | $6.68K (-33.2%) started 2025-10-15 |
| 5Y ago | N/A | $440.92 (-95.6%) started 2021-10-15 |
| 10Y ago | N/A | $3.74K (-62.6%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | ACCD | TDOC |
|---|---|---|
| Market capi | N/A | $1.17B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | -8.23 |
| Price/Salesi | 1.39 | N/A |
| EV/Revenuei | N/A | 0.56 |
| Analyst targeti | N/A | $7.67 |
| Target upsidei | N/A | +18.68% |
| Metric | ACCD | TDOC |
|---|---|---|
| Revenue growthi | N/A | -4.00% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | +7.67% |
| Operating margini | N/A | -5.68% |
| Profit margini | N/A | -7.13% |
| ROIC proxyi | N/A | -12.98% |
| Return on equityi | N/A | -12.98% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | -0.26 | 2.13 |
| Debt/equityi | N/A | 79.09 |
| Current ratioi | N/A | 0.83 |
| Quick ratioi | N/A | 0.73 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ACCD | TDOC |
|---|---|---|---|
| 1Y | Growthi | N/A | -33.22% |
| CAGRi | N/A | -33.24% | |
| Volatilityi | N/A | 60.80% | |
| Sharpe ratioi | N/A | -0.42 | |
| Sortino ratioi | N/A | -0.58 | |
| Max drawdowni | N/A | 52.75% | |
| Current drawdowni | N/A | 38.58% | |
| Avg drawdowni | N/A | 29.00% | |
| Ulcer Indexi | N/A | 31.95% | |
| Max daily dropi | N/A | 28.32% | |
| Max wkly dropi | N/A | 28.31% | |
| 5Y | Growthi | N/A | -95.59% |
| CAGRi | N/A | -46.44% | |
| Volatilityi | N/A | 65.59% | |
| Sharpe ratioi | N/A | -0.69 | |
| Sortino ratioi | N/A | -0.94 | |
| Max drawdowni | N/A | 97.10% | |
| Current drawdowni | N/A | 96.13% | |
| Avg drawdowni | N/A | 84.63% | |
| Ulcer Indexi | N/A | 86.39% | |
| Max daily dropi | N/A | 40.15% | |
| Max wkly dropi | N/A | 43.25% | |
| 10Y | Growthi | N/A | -62.57% |
| CAGRi | N/A | -9.37% | |
| Volatilityi | N/A | 60.81% | |
| Sharpe ratioi | N/A | 0.07 | |
| Sortino ratioi | N/A | 0.10 | |
| Max drawdowni | N/A | 98.48% | |
| Current drawdowni | N/A | 97.97% | |
| Avg drawdowni | N/A | 54.31% | |
| Ulcer Indexi | N/A | 67.31% | |
| Max daily dropi | N/A | 40.15% | |
| Max wkly dropi | N/A | 43.25% |
| Category | ACCD | TDOC |
|---|---|---|
| Company | Accolade, Inc. | Teladoc Health, Inc. |
| Sector | Healthcare Technology | Healthcare |
| Industry | N/A | Health Information Services |
| Core business | Personalized health navigation and advocacy platform sold to employers and health plans. Accolade combines human health assistants with technology to guide members through complex healthcare decisions, reducing cost and improving outcomes. | The world's largest telehealth platform, offering virtual primary care, mental health (BetterHelp), chronic disease management, and specialty virtual care. Teladoc serves employers, health plans, and hospitals globally. |
| Investor focus | Revenue per member (PEPM), employer client retention, expansion into mental health and complex care, and path to profitability. | BetterHelp mental health revenue and margin recovery, integrated care member growth, chronic condition management program enrollment, and path to EBITDA profitability. |
- Personalized human-plus-technology health navigation model drives high member engagement vs purely virtual care alternatives
- Strong employer client retention once integrated into benefits programs creates durable recurring revenue
- PlushCare acquisition expanded Accolade into direct primary and mental health virtual care
- Teladoc is the global telehealth market leader with the largest network of clinicians and most diversified virtual care products
- BetterHelp is one of the largest consumer mental health platforms globally by user base
- Multi-product platform with whole-person virtual care (primary, mental, chronic condition) creates employer cross-sell opportunities
- Accolade remains unprofitable with significant EBITDA losses as it scales its human advocacy workforce
- Employer HR decision cycles are long — new client ramp takes 12–18 months before revenue is recognized
- Competition from larger benefits platforms (Teladoc, CVS Health) could commoditize health navigation
- Teladoc took massive goodwill impairment charges on the Livongo acquisition — the $18.5B acquisition has been deeply value-destructive
- BetterHelp faces increasing competition from mental health startups, health plans, and employer-sponsored programs at lower price points
- Path to sustained EBITDA profitability requires significant margin improvement from current levels
Compare more than two at a time
This page is a fixed writeup on ACCD and TDOC. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ACCD and TDOC, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.